Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization

Nature Communications

Volumn 8, Issue , 2017, Pages

  Senturk, Serif ^a   Shirole, Nitin H ^a,b   Nowak, Dawid G ^a   Corbo, Vincenzo ^a   Pal, Debjani ^a,b   Vaughan, Alexander ^a   Tuveson, David A ^a   Trotman, Lloyd C ^a   Kinney, Justin B ^a   Sordella, Raffaella ^a  

^a Simons Center for Quantitative Biology   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAS9 PROTEIN; CRE RECOMBINASE; ELONGATION FACTOR 1ALPHA; FKBP12 PROTEIN; GUIDE RNA; LENTIVIRUS VECTOR; LIGAND; PROTEIN; PROTEIN P53; SHIELD 1; UNCLASSIFIED DRUG; CRISPR ASSOCIATED PROTEIN; INTEGRASE; TAMOXIFEN;

ALLELE; BIOMANIPULATION; CELLS AND CELL COMPONENTS; ENZYME ACTIVITY; GENE EXPRESSION; LIGAND;

A-549 CELL LINE; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAS9 EXPRESSION SYSTEM; CONTROLLED STUDY; CRISPR CAS SYSTEM; ENZYME SPECIFICITY; ESSENTIAL GENE; GENE CASSETTE; GENE CONTROL; GENE EDITING; GENE EXPRESSION; GENE FUNCTION; GENE FUSION; GENE IDENTIFICATION; GENE INTERACTION; GENE TARGETING; GENETIC STABILITY; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MALE; MOUSE; NONHUMAN; PC9 CELL LINE; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CHEMISTRY; FIBROBLAST; GENETICS; LENTIVIRUS; METABOLISM; PROCEDURES; PROTEIN STABILITY; TIME FACTOR;

A549 CELLS; ANIMALS; CRISPR-ASSOCIATED PROTEINS; CRISPR-CAS SYSTEMS; FIBROBLASTS; GENE EDITING; HUMANS; INTEGRASES; LENTIVIRUS; LIGANDS; MICE; PROTEIN DOMAINS; PROTEIN STABILITY; RNA, GUIDE; TAMOXIFEN; TIME FACTORS;

EID: 85013676135     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms14370     Document Type: Article

References (39)

1. Hannon, G. J. and Rossi, J. J. Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378 (2004).
2. Tuveson, D. A. and Jacks, T. Technologically advanced cancer modeling in mice. Curr. Opin. Genet. Dev. 12, 105-110 (2002).
3. Dickins, R. A. et al. Tissue-specific and reversible RNA interference in transgenic mice. Nat. Genet. 39, 914-921 (2007).
4. Li, T. et al. High-efficiency TALEN-based gene editing produces diseaseresistant rice. Nat. Biotechnol. 30, 390-392 (2012).
5. Wood, A. J. et al. Targeted genome editing across species using ZFNs and TALENs. Science 333, 307 (2011).
6. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 333, 307 (2011).
7. Hsu, P. D. et al. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014).
8. Mali, P. et al. RNA-guided human genome engineering via Cas9. Cell 157, 1262-1278 (2014).
9. Pattanayak, V. et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31, 839-843 (2013).
10. Cho, S. W. et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132-141 (2014).
11. Banaszynski, L. A. et al. A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules. Cell 126, 995-1004 (2006).
12. Egeler, E. L. et al. Ligand-switchable substrates for a ubiquitin-proteasome system. J. Biol. Chem. 286, 31328-31336 (2011).
13. Clackson, T. et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc. Natl Acad. Sci. 93, 10437-10442 (1998).
14. Bonger, K. M. et al. Small-molecule displacement of a cryptic degron causes conditional protein degradation. Nat. Chem. Biol. 7, 531-537 (2011).
15. Banaszynski, L. A. et al. Chemical control of protein stability and function in living mice. Nat. Med. 14, 1123-1127 (2008).
16. Kuscu, C. et al. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat. Biotechnol. 32, 677-683 (2014).
17. Zou, Y. et al. Functions of human replication protein A (RPA) from DNA replication to DNA damage and stress responses. J. Cell. Physiol. 208, 267-273 (2006).
18. Zou, L. et al. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542-1548 (2003).
19. Dutta, A. et al. Cdc2 family kinases phosphorylate a human cell DNA replication factor, RPA, and activate DNA replication. EMBO J. 11, 2189-2199 (1992).
20. McJunkin, K. et al. Reversible suppression of an essential gene in adult mice using transgenic RNA interference. Proc. Natl Acad. Sci. 108, 7113-7118 (2011).
21. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in an acute myeloid leukemia. Nature 478, 524-528 (2011).
22. Yao, Z. et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl Acad. Sci. 107, 15535-15540 (2010).
23. Zuber, J. et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat. Biotechnol. 29, 79-83 (2011)
24. Jiang, H. et al. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat. Chem. Biol. 7, 92-100 (2011).
25. Jiang, H. et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 23, 1895-1909 (2009).
26. Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324-338 (2015).
27. Maddalo, D. et al. In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature 516, 423-427 (2014).
28. Xue, W. et al. CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature 514, 380-384 (2014).
29. Sanchez-Rivera, F. J. et al. Rapid modeling of cooperating genetic events in cancer through somatic genome editing. Nature 516, 428-431 (2014).
30. Tyner, S. D. et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45-53 (2002).
31. Ventura, A. et al. Restoration of p53 function leads to tumor regression in vivo. Nature 445, 661-665 (2007).
32. Premsrirut, P. K. et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145, 145-158 (2011).
33. Dow, L. E. et al. Inducible in vivo genome editing with CRISPR-Cas9. Nat. Biotechnol. 33, 390-394 (2015).
34. Zetsche, B. et al. A split-Cas9 architecture for inducible genome editing and transcription modulation. Nat. Biotechnol. 33, 139-142 (2015).
35. Nihongaki, Y. et al. Photoactivable CRISPR-Cas9 for optogenetic genome editing. Nat. Biotechnol. 33, 755-760 (2015).
36. Davis, K. M. et al. Small molecule triggered Cas9 protein with improved genome-editing specificity. Nat. Chem. Biol. 11, 316-318 (2015).
37. Wright, A. V. et al. Rational design of a split-Cas9 enzyme complex. Proc. Natl Acad. Sci. 112, 2984-2989 (2015).
38. Wang, T. et al. Genetic screens in human cells using the CRISPR-Cas9 system. Science 343, 80-84 (2014).
39. Shi, J. et al. Discovery of cancer drugs targets by CRISPR-Cas9 screening of protein domains. Nat. Biotechnol. 33, 661-667 (2015).